- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03906487
Self Defining Memories in Women Victims of Intimate Partner Violence. (SOI-MEM)
Self Defining Memories in Women Victims of Intimate Partner Violence: a Pilot Study.
Study Overview
Status
Conditions
Detailed Description
Intimate partner violence among women is associated to identity problems. Indeed, the victims have a poor self esteem and difficulties to express their own wishes. In this study investigators suggest an analysis of a type of memory, that is known to be essential, to profile an identity functioning: self-defining memories. To date, no study has explored SDM in women with IPV. The characteristics of the SDM in women victims of IPV will be compared to a group of women who has never been diagnosed in this situation. Those memories could be used in therapy. A French adaptation of the questionnaire proposed by Singer & Moffitt (1992) will be used (Berna et al., 2011a, 2011b) for the assessment of SDM.
Four elements will be study: specificity, meaning, content, affect.
The two groups will have two visits:
- the first to verify inclusion criteria and assessed psychotraumatic and depressive symptoms;
- the last to characterize the SDM.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Toulouse, France
- Recruiting
- University Hospital Toulouse
-
Contact:
- Damien PIERRE, MD
- Email: pierre.d@chu-toulouse.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
For all participants:
- French mother tongue.
- Informed consent.
- Affiliated to social security
For women who are victims of IPV only:
- Having at least two physical aggressions
- To meet criterion A of the diagnosis of PTSD according to the Diagnostic and Statistical Manual of Mental Disorders DSM (DSM-5) (evaluated using the Mini International Neuropsychiatric Interview, MINI)
For women of the control group only:
- None a victim of IPV
Exclusion Criteria:
For all participants:
- Neurological pathology, brain damage.
- History of head trauma with loss of consciousness.
- Severe, progressive somatic pathology
- Psychotherapy in progress
- Taking psychotropic drugs or beta-blockers (because of their potential impact on memory capacity)
- Pregnant or lactating women
- Under a legal regime for the protection of adults
For women who are victims of IPV only:
- Antecedent or presence of PTSD other than that related to IPV
- History or presence of progressive mental disorders (Axis I DSM-5 - evaluated using Mini International Neuropsychiatric Interview, MINI)
For women of the control group only:
History or presence of progressive mental disorders including PTSD (Axis I DSM-5 - evaluated using Mini International Neuropsychiatric Interview, MINI)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Intimate partner violence
The women in this arm must have suffered at least two physical aggressions.
They will be recruited in the study as part of their coming to the consultation of intentional injury of the medico-legal unit of the University Hospital Toulouse.
|
This group will have two visits:
|
|
Active Comparator: Control group
The women in this group are women who have never experienced domestic violence or have experienced a potentially traumatic event.
These women will be recruited by a call for volunteers.
|
This group will have two visits:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Description of five Self Defining Memories.
Time Frame: 7 to 10 days after inclusion visit
|
These memories are declined in four dimensions: specificity, content, meaning and emotional valence.
Investigator will get a proportion of memories which are specific, which are negative, positive or neutral, which have an integrative meaning and which are associated to violence for IPV victims.
The results of Self Defining Memories will be compared between a group of IPV victims and a control group.
|
7 to 10 days after inclusion visit
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportions of SDM whose content is associated with discomfort in IPV victims compared to those of control.
Time Frame: 7 to 10 days after inclusion visit
|
7 to 10 days after inclusion visit
|
|
|
Proportions of SDM whose emotional valence is associated with a feeling of redemption or contamination in IPV victims compared to those of control.
Time Frame: 7 to 10 days after inclusion visit
|
7 to 10 days after inclusion visit
|
|
|
Relationships between the 4 dimensions of SDM and psychotraumatic symptoms in IPV victims.
Time Frame: 7 to 10 days after inclusion visit
|
These symptoms will be measured via the Posttraumatic Stress Disorder Checklist (PCL-5 scale).This is a self-questionnaire to assess the main symptoms of Post traumatic stress disorder.
It has 20 items that evaluate the intensity and frequency of symptoms in the previous month using scores from 1 to 4.The higher the score, the more important the trauma.
|
7 to 10 days after inclusion visit
|
|
Relationships between the 4 dimensions of SDM and depressive symptoms in IPV victims.
Time Frame: 7 to 10 days after inclusion visit
|
These symptoms will be measured via the Beck Depressin Inventory (BDI) scale: this is a self-questionnaire to assess the severity of depressive symptoms using 21 items. Once the test is completed, a score is made by decounting, then compared according to the score, thus determining the severity of the depression: 0 - 9: indicates a minor depression 10 - 18: indicates slight depression 19 - 29: indicates moderate depression 30 - 63: indicates severe depression |
7 to 10 days after inclusion visit
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Damien PIERRE, MD, Chu Toulouse
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- RC31/19/0051
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Domestic Violence
-
University of the Virgin IslandsUnknownDomestic Violence | Domestic AbuseVirgin Islands (U.S.)
-
Medical Research Council, South AfricaUniversity of GhanaUnknownSexual Violence | Domestic Violence | Physical ViolenceGhana
-
Johns Hopkins UniversityUniversity of Pittsburgh; Office of Research on Women's Health (ORWH); Futures...CompletedViolence, Domestic | Violence, SexualUnited States
-
Funmilola OlaOlorunUniversity of IbadanCompletedDomestic Violence | Violence | AttitudeNigeria
-
Karolinska InstitutetRegion Stockholm; Jane and Dan Olsson Foundation for Scientific PurposesCompletedDomestic Violence | Family Violence | Intimate-partner ViolenceSweden
-
Johns Hopkins UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedDomestic Violence | Intimate Partner ViolenceUnited States
-
NMP Medical Research InstituteWarwick Research Services; Arsha Vidya Study Centre, Tamilnadu, IndiaCompletedDomestic Violence | Intimate Partner ViolenceIndia
-
University of UtahCompletedDomestic Violence | Intimate Partner ViolenceUnited States
-
University of PittsburghCompletedViolence in Adolescence | Domestic ViolenceUnited States
-
University of SheffieldUniversity of HuddersfieldCompleted
Clinical Trials on Assessment measures MINI, PCL5 and BDI-II and definition of 5 SDM
-
University of ValenciaAsociación Parkinson ValenciaWithdrawnParkinson's Disease | Alzheimer's Disease | Healthy Older AdultsSpain
-
Mahidol UniversityCompletedScreening Tool for Depresion in Cancer Pain PatientsThailand
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedStage III Anal Cancer AJCC v8 | Anal Canal Squamous Cell Carcinoma | Stage IIB Anal Cancer AJCC v8 | Stage IIIA Anal Cancer AJCC v8 | Stage IIIB Anal Cancer AJCC v8 | Stage IIIC Anal Cancer AJCC v8 | Stage I Anal Cancer AJCC v8 | Stage II Anal Cancer AJCC v8 | Stage IIA Anal Cancer AJCC v8United States
-
Prof. Dr. Benedikt SchoserCompleted
-
NRG OncologyNational Cancer Institute (NCI)Active, not recruitingEpstein-Barr Virus Infection | Stage III Nasopharyngeal Carcinoma | Stage IVA Nasopharyngeal Carcinoma | Stage IVB Nasopharyngeal Carcinoma | Stage II Nasopharyngeal CarcinomaUnited States, Canada, Taiwan, Puerto Rico, Australia, Hong Kong, Singapore, China
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)Active, not recruitingAnal Squamous Cell Carcinoma | Anal Basaloid Carcinoma | Anal Canal Cloacogenic Carcinoma | Metastatic Anal Canal Carcinoma | Recurrent Anal Canal Carcinoma | Stage IIIB Anal Canal Cancer | Stage IV Anal Canal CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedStage III Bladder Cancer AJCC v8 | Stage III Renal Pelvis Cancer AJCC v8 | Stage III Ureter Cancer AJCC v8 | Stage III Urethral Cancer AJCC v8 | Stage IIIA Bladder Cancer AJCC v8 | Stage IIIB Bladder Cancer AJCC v8 | Urethral Urothelial Carcinoma | Stage II Bladder Cancer AJCC v8 | Stage II Renal Pelvis... and other conditionsUnited States
-
Memorial Sloan Kettering Cancer CenterUniversity of Texas Southwestern Medical Center; Wake Forest UniversityActive, not recruitingBreast CancerUnited States
-
Hadassah Medical OrganizationRecruitingHealthy VolunteersIsrael
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingSinonasal Undifferentiated Carcinoma | Locally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma | Nasal Cavity and Paranasal Sinus Poorly Differentiated Carcinoma | Stage II Nasal Cavity and Paranasal Sinus Cancer AJCC v8 | Stage III Nasal Cavity and Paranasal Sinus Cancer... and other conditionsUnited States